Rational PROTAC design enabled by integrated in silico molecular modeling and in vitro biomimetic affinity assessment
Rational PROTAC design enabled by integrated in silico molecular modeling and in vitro biomimetic affinity assessment
批准号:
10728205
负责人:
QUAN JASON CHENG
金额:
$22.67万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-08-01 至 2025-07-31
关键词:
AffectAffinityAttentionBackBindingBinding ProteinsBiological AssayBiomedical ResearchBiomimeticsBiophysicsCell membraneCellsComplexComputer ModelsDiseaseDoseDrug TargetingDrug resistanceEnvironmentExcisionGoalsIn VitroInvestigationKnowledgeLabelLeftLigandsLipidsLysosomesMalignant NeoplasmsMeasurementMembraneMembrane LipidsMethodologyModalityModelingMolecularMutagenesisPropertyProtacProtein DynamicsProteinsReceptor Protein-Tyrosine KinasesReportingResearchRoleStructureStructure-Activity RelationshipSurface Plasmon ResonanceSystemTechnologyTheoretical modelTherapeuticThinnessUbiquitinationWorkanaplastic lymphoma kinasedesigndrug candidatedrug developmentexperienceexperimental studyfabricationin silicoin vitro Assayinhibitorinnovationinsightinterestmolecular modelingmolecular recognitionmulticatalytic endopeptidase complexnovel drug classprotein degradationscreeningside effectsmall moleculestemubiquitin-protein ligase
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Rational PROTAC design enabled by integrated in silico molecular modeling and in vitro
biomimetic affinity assessment
Proteolysis targeting chimeras, or PROTACs, have received considerable attention in recent years as
a new class of drugs as compared to traditional inhibitors. These small molecules target selective degradation
of proteins of interest utilizing cell’s native protein degradation machinery including proteosomes and
lysosomes. The benefits of PROTACs stem from an entirely different paradigm of protein targeting, which
provides a unique path to target previously “undruggable” proteins and allows for smaller doses and thus
lower side-effects. However, the complex mechanism of action has left a large knowledge gap towards the
understanding of molecular interactions in different stages, especially on factors that control and stabilize the
ternary complex that leads to ubiquitination and removal. In addition, existing technology lacks of strategies
to model and confirm the linker region of the PROTAC for their roles in affecting the affinities of the warheads
and contributing to the stability of the complex. There has been no report that includes the dynamic membrane
in molecular recognition modeling. A new technical platform that can identify key parameters that impact
formation of stable ternary complex and has the capability of screening molecular interactions with detailed
information on structural insights is highly desired.
To fill the unmet need, we propose to develop a collaborative work plan via a combination of in silico
modeling and in vitro surface plasmon resonance (SPR)-based affinity assessment. We aim to identify
features that lead to formation of stable ternary complexes for efficient PROTAC design. To establish and
prove the technical feasibility, we will study anaplastic lymphoma kinase (ALK), a transmembrane receptor
tyrosine kinase that is an important drug target for a variety of cancers, and an E3 ligase CRBN which has
been used to promote protein degradation. Specifically, we propose three aims: Aim 1. Establish a molecular
modeling platform for rational PROTAC design. The platform incorporates protein dynamics and inputs from
experiments and can adapt various experimental settings such as membrane environment used in SPR. Aim
2. Build and characterize modeled PROTACs and biomimetic membranes. This includes generating
PROTAC-compatible membrane mimics and structural characterization of the interfaces for membrane-bound
proteins for SPR analysis. Aim 3. Investigate interaction properties of PROTAC candidates’ in biomimetic
membranes. This includes on-line in vitro experiments and screening for the PROTACs at stabilizing the
ternary complexes. The identification of stable PROTAC complexes will be used into further exploration into
the understanding of the structure-function relationship of the system.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Glycolipid biointerface to decipher disease-implicated ganglioside-protein interactions
-
批准号:10737003
-
项目类别:
-
资助金额:$33.14万
-
财政年份:2023
-
负责人:QUAN JASON CHENG
-
依托单位:
Label-Free Microarray Profiling of Phosphoinositide-PDZ Domain Interactions
-
批准号:7660991
-
项目类别:
-
资助金额:$20.71万
-
财政年份:2009
-
负责人:QUAN JASON CHENG
-
依托单位:
Label-Free Microarray Profiling of Phosphoinositide-PDZ Domain Interactions
-
批准号:7771777
-
项目类别:
-
资助金额:$17.97万
-
财政年份:2009
-
负责人:QUAN JASON CHENG
-
依托单位:
海外基金